Income Statement
VIVOS THERAPEUTICS, INC.
VVOS
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY |
|---|---|---|---|---|---|
|
Revenue
|
15.03 | 13.80 | 16.02 | 16.89 | 13.07 |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
9.02 | 8.27 | 10.02 | 12.60 | 10.41 |
|
Operating Expenses
|
20.19 | 25.57 | 35.05 | 32.99 | 22.45 |
|
Research & Development
|
- | - | - | - | - |
|
Selling, General & Administrative
|
17.88 | 22.48 | 29.04 | 25.79 | 16.09 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-11.17 | -17.30 | -25.03 | -20.38 | -12.04 |
|
Non-Operating Income
|
-0.04 | -3.71 | -1.19 | -0.09 | 0.02 |
|
Interest Income
|
- | - | - | 0.12 | 0.08 |
|
Interest Expense
|
- | - | - | 0.01 | 0.10 |
|
Other Non-Op Income / Expense
|
-0.11 | -0.21 | -0.19 | -0.01 | - |
|
Income Before Tax
|
-11.14 | -13.58 | -23.85 | -20.29 | -12.06 |
|
Income Tax Expense
|
0.00 | 0.00 | 0.00 | 0.00 | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-11.14 | -13.58 | -23.85 | -20.29 | 12.06 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-10.59 | -16.68 | -24.36 | -19.65 | -11.32 |
|
Earnings Per Share (Basic)
|
-2.22 | -11.14 | -1.04 | - | - |
|
Diluted EPS
|
-2.22 | -11.14 | - | - | - |
|
Weighted Average Shares
|
5.02 | 1.22 | 23,012.12 | - | - |
|
Diluted Weighted Avg Shares
|
5.02 | 1.22 | - | - | - |
|
Comprehensive Income
|
- | - | - | - | - |